Mylan's competition on Teva's Copaxone is priced in. Debt reduction in the billions will ease investor fears.Buy Teva when it gets to $10 (currently $11). $TEVA, Teva Pharmaceutical Industries Limited / H1 Related: Endo Intl took a hit but is bouncing back strong on deep value. Allergan, which sold the generic unit, faces competition on its own key products. Valeant Pharma (VRX) reports this week.Agree or disagree?Now! Login to vote. Comment below.